Patient-derived NK treatment in vitro and in vivo in OC mouse models reduced tumour migration and invasion with the expansion of CD4+ and CD8+ T-cell populations, as well as IFN-γ production, leading to improved survival rates [101]. This evidence concerns the gene CD8A and neoplasm.